Exhibit 99.2
| Tom Wrankmore, Ahornstraße 10, 06246 Bad Lauchstädt | ![]() |
CS Diagnostics Pharma GmbH Mr. Thomas Fahrhöfer
Müller-zu-Bruck-Straße 12
83052 Bruckmühl
Date
2023-9-4
Dear Mr. Fahrhöfer,
You have asked me to evaluate the process for the production of CS Protect-Hydrogel on the basis of the future economic benefits to be achieved for the CS Diagnostics Group as of September 30, 2023. I would like to comment on this as follows:
Description and identification of the intangible asset
The CS Protect-Hydrogel is a hydrogel-based tissue spacer. It is used in radiation therapy to increase the distance between cancer cells and healthy tissue and thus protect healthy tissue from damage caused by high doses of radiation.
Currently, hydrogel spacers are used exclusively in the treatment of prostate cancer. Here, the spacer pushes the rectum away from the prostate, thus reducing rectal damage from radiation therapy.
The hydrogel spacer is injected once in liquid form through a thin needle into the space between cancer cells and healthy tissue and is broken down by the body after about six months.
The CS Protect-Hydrogel is a "ready-to-use" product, which is sterile packed and can be applied directly. The hydrogel can be used in radiotherapy for prostate, cervical, esophageal, bladder and breast cancer.
|
| Seite 1 von 9 |
The CS Hydrogel was developed by CS Diagnostics Pharma GmbH and CS Interpharm LLC, both companies of the CS Diagnostics Group, in cooperation with the Rheinisch-Westfälische Technische Hochschule Aachen and the DWI - Leibniz-Institut für Interaktive Materialien e.V. The patent application was filed with the German Patent and Trademark Office in 2023. The applicant for the patent is the DWI - Leibniz Institute for Interactive Materials e.V., which has granted CS Diagnostics Pharma GmbH an exclusive right to use the invention.
Competitive environment
Competitor products
In terms of tissue spacers, hydrogel-based as well as hyaluronic acid-based spacers are used in cancer treatment. However, hyaluronic acid spacers are niche products with a small market share.
In the case of hydrogel spacers, a competitor product from Boston Scientific Corporation is currently available on the market. The competitor product SpaceOAR Hydrogel System was developed in 2010 by Augmentix, Inc. The shares in Augementix, Inc. were fully acquired by Boston Scientific Corporation in 2018 for a fixed purchase price of USD 500 million plus a variable purchase price component of USD 100 million upon achievement of certain sales targets. The competitor product has been further developed, is currently marketed under the SpaceOAR Vue Hydrogel trademark, and is approved exclusively for use in prostate radiation. The product marketed by Boston Scientific Corporation consists of three components that are mixed in a predetermined sequence and drawn into a syringe by a trained and skilled person.
The molecule of the CS Protect-Hydrogel differs significantly from the molecule of the competitor product. According to research by the Rheinisch-Westfälische Technische Hochschule Aachen or the DWI - Leibniz Institute for Interactive Materials e.V. and the CS Diagnostics Group, patent infringements are not to be expected.
Unique selling proposition (USP)
The CS Protect-Hydrogel is a more advanced hydrogel both from the molecular structure, chemical physical properties and medical applications. Compared to the competitor product of Boston Scientific Corporation, CS Protect-Hydrogel has the following practical, hygienic, medical and economic advantages:
Practical advantages:
| - | easy application of the CS Protect-Hydrogel since it is a "ready-to-use" product |
| - | avoidance of a further work step |
| Seite 2 von 9 |
Hygienic advantages:
| - | immediate application of the CS Protect-Hydrogel after removal from sterile packaging |
| - | no risk of contamination due to preparation and assembly of the product |
| - | exclusion of another hygienic risk area within the treatment room |
Medical advantages:
| - | no risk of wrong mixture (especially wrong sequence) and therefore no potential patient's missed appointment |
| - | extended application range - besides prostate cancer also for cervical, esophageal, bladder and breast cancer |
| - | hypofractionation possible - significantly fewer treatment sessions per patient |
| - | dose escalation possible - acceleration of radiation therapy |
Economic advantages:
| - | lower personnel costs during treatment due to the elimination of assistance for mixing the hydrogel |
| - | lower room utilization costs per patient as there is no longer a risk of patients having to be treated again due to incorrect mixtures (higher number of patients per treatment room) |
| - | lower cleaning costs due to the ready-to-use principle |
| - | fewer lawsuits and/or insurance claims due to incorrectly mixed hydrogels requiring the patient to be treated again |
| - | lower purchase price for the clinics than for the competitor product |
Market entry barriers
The CS Protect-Hydrogel is a medical device and requires registration or approval by the respective governmental authorities, in particular the Food and Drug Administration (FDA) in the USA or the Federal Institute for Drugs and Medical Devices (BfArM) after CE testing and certification in Germany. Registration or approval is preceded by a testing procedure. The CS Diagnostics Group anticipates a period of 6 to 12 months for approval in the U.S. and 6 to 8 months for the testing procedure and registration of the CS Protect-Hydrogel in Germany.
Since a competitor product is already available on the market and is used worldwide for prostate irradiation, CS Protect-Hydrogel does not need to be re-explained or advertised for use in prostate irradiation. Extensive information and advertising is required for the treatment of other types of cancer.
| Seite 3 von 9 |
The CS Protect-Hydrogel is a further developed substitute product for the competing product of Boston Scientific Corporation on the market. Due to the easier handling, the lower medical risks and cost risks, and the expanded scope of application, the CS Diagnostics Group expects that the respective purchasing departments of clinics (including specialty clinics) and hospitals will quickly adopt and list the CS Protect-Hydrogel in their portfolios.
Valuation of future economic benefits
Total market and market share
Hydrogel spacers are used in radiotherapy for prostate, esophageal, bladder, breast and cervical cancer. The use of hydrogel spacers is contraindicated in approximately 10 % of irradiated patients. For the major markets in the USA and the European Union, the potential use is as follows:
|
new cases per patients |
thereof irradiation
|
thereof
patients |
application
patients | |||
| European Union1) |
209,897 | |||||
| Prostate Cancer | 335,514 | 25.0 | 83,879 | 8,388 | 75,491 | |
| Breast Cancer | 355,457 | 40.0 | 142,183 | 14,218 | 127,965 | |
| Bladder Cancer | 157,484 | 3.0 | 4,725 | 473 | 4,252 | |
| Cervical cancer | 30,447 | 5.0 | 1,522 | 152 | 1,370 | |
| Esophageal Cancer | 30,327 | 3.0 | 910 | 91 | 819 | |
| USA2) | 175,503 | |||||
| Prostate Cancer | 288,300 | 25.0 | 72,075 | 7,208 | 64,867 | |
| Breast Cancer | 297,790 | 40.0 | 119,116 | 11,912 | 107,204 | |
| Bladder Cancer | 82,290 | 3.0 | 2,469 | 247 | 2,222 | |
| Cervical cancer | 13,960 | 5.0 | 698 | 70 | 628 | |
| Esophageal Cancer | 21,560 | 3.0 | 647 | 65 | 582 | |
| Total | 385,400 | |||||
1) Data source: International Agency for Research on Cancer (Data basis: 2020); https://gco.iarc.fr/
2) Data source: American Cancer Society (Data basis: 2023); https://www.cancer.org/
| Seite 4 von 9 |
With one application per patient, the annual sales potential of hydrogel spacers in the European Union and the USA is 385,400 units.
In addition to the CS Protect-Hydrogel, one competitor product is used worldwide. The CS Diagnostics Group believes that a market share of approximately 50 % can be achieved for the CS Protect- Hydrogel in the medium term due to its simpler handling, lower medical risks and cost risks, and expanded scope of application.
Prices and recoverable amounts
The competitor product of CS Protect-Hydrogel is currently offered for sale to clinics and hospitals at market prices ranging from EUR 1,100 to EUR 1,900, with prices of around USD 2,000 in the USA and between EUR 1,100 and EUR 1,800 in the European Union.
The CS Diagnostics Group will position the CS Protect-Hydrogel as a "ready-to-use" product below these prices. The Group is expected to call selling prices between EUR 1,100 to EUR 1,300 per unit in the European Union and USD 2,000 (i.e. approx. EUR 1,900) per unit in the USA.
With an expected market share of around 50 %, annual revenues of EUR 282 million to EUR 303 million would thus be achievable.
Future economic benefits
The future economic benefits from the CS Protect-Hydrogel for the CS Diagnostics Group results from the proceeds from the sale less the manufacturing costs of the hydrogel and the variable distribution costs.
In preliminary discussions of the CS Diagnostics Group with potential manufacturers of the hydrogel, manufacturing prices between EUR/unit 150 (European Union) to 180 (USA) have been promised. As variable distribution costs, the CS Diagnostics Group expects 25% of sales revenues.
The CS Diagnostics Group assumes a product life cycle of approximately 10 years from market launch. Market launch is expected after approval or registration of the product in 2025. A compound annual growth rate (CAGR) of 4.9 % p.a. is assumed for the overall market.
| Seite 5 von 9 |
Overall, this results in the following assumptions for assessing the economic benefits of the CS hydrogel:
| EU (27) | USA | ||||
| Selling price | EUR/unit | 1,100 | 1,900 | ||
| Production price | EUR/unit | 150 | 180 | ||
| Distribution costs | % | 25.0 | 25.0 | ||
| Compound annual growth rate (CAGR) | % p.a. | 4.9 | 4.9 | ||
According to the planning of the CS Diagnostics Group, the target values for the market share of approx. 50 % will be achieved as follows:
| Target value Share of total market (in %) | |||||
year |
Prostate Cancer |
Breast Cancer |
Bladder Cancer |
Cervical cancer |
Esophageal Cancer |
| 2025 | 10 | 5 | 5 | 5 | 5 |
| 2026 | 20 | 10 | 10 | 10 | 10 |
| 2027 | 30 | 20 | 20 | 20 | 20 |
| 2028 | 40 | 30 | 30 | 30 | 30 |
| 2029 | 50 | 40 | 40 | 40 | 40 |
| 2030 | 50 | 50 | 50 | 50 | 50 |
| 2031 | 50 | 50 | 50 | 50 | 50 |
| 2032 | 50 | 50 | 50 | 50 | 50 |
| 2033 | 50 | 50 | 50 | 50 | 50 |
| 2034 | 50 | 50 | 50 | 50 | 50 |
| Seite 6 von 9 |
Taking these assumptions into account, the following future cash flows and their present values as of September 30, 2023 (risk- and maturity-equivalent interest rate of 10 % p.a.) result from the CS Protect-Hydrogel:
| year |
Sales |
Expenses |
Profit
margin / mio. EUR |
Net present value | |||
| 2025 | 42 | 15 | 27 | 23 | |||
| 2026 | 89 | 32 | 57 | 44 | |||
| 2027 | 162 | 58 | 103 | 72 | |||
| 2028 | 241 | 87 | 154 | 98 | |||
| 2029 | 328 | 119 | 210 | 121 | |||
| 2030 | 394 | 143 | 252 | 132 | |||
| 2031 | 414 | 150 | 264 | 126 | |||
| 2032 | 434 | 157 | 277 | 120 | |||
| 2033 | 455 | 165 | 291 | 115 | |||
| 2034 | 478 | 173 | 305 | 109 | |||
| Totals | 3,038 | 1,099 | 1,939 | 961 | |||
The sum of the present values and thus the future economic benefit over the expected product life cycle is therefore EUR 961 million.
| Seite 7 von 9 |
Sensitivity analysis
The future economic benefit of the CS Protect-Hydrogel is mainly dependent on market penetration and the achievement of market share as well as the achievable selling prices per unit. Changes in these assumptions result in the following present values of the future cash flows from CS Protect- Hydrogel for the sales markets of the European Union and the USA:
| market share (%): |
20 | 30 | 40 | 50 | 60 |
| selling price (per unit): | |||||
| EU (27) | |||||
| 950 | 126 | 189 | 252 | 315 | 378 |
| 1,000 | 134 | 201 | 268 | 336 | 403 |
| 1,050 | 143 | 214 | 285 | 357 | 428 |
| 1,100 | 151 | 227 | 302 | 378 | 453 |
| 1,150 | 159 | 239 | 319 | 399 | 478 |
| USA | |||||
| 1,750 | 212 | 318 | 424 | 530 | 637 |
| 1,800 | 219 | 329 | 438 | 548 | 658 |
| 1,850 | 226 | 339 | 452 | 566 | 679 |
| 1,900 | 233 | 350 | 466 | 583 | 700 |
| 1,950 | 240 | 360 | 481 | 601 | 721 |
| Totals | |||||
| 950/1,750 | 338 | 507 | 676 | 845 | 1,014 |
| 1,000/1,800 | 353 | 530 | 707 | 884 | 1,060 |
| 1,050/1,850 | 369 | 553 | 738 | 922 | 1,107 |
| 1,100/1,900 | 384 | 576 | 769 | 961 | 1,153 |
| 1,150/1,950 | 400 | 600 | 799 | 999 | 1,199 |
| Seite 8 von 9 |
Valuation of the intangible asset
The value of the CS Diagnostics Group's right to use CS Protect-Hydrogel is mainly dependent on the market penetration and the market share achieved as well as the achievable sales prices. In the most likely scenario of a market share of 50 % and sales prices of EUR/unit 1,100 (EUR (27)) and EUR/unit 1,900 (USA), the economic benefit as the net present value of future cash surpluses as of September 30, 2023 is EUR 961 million.
Yours sincerely,

Tom Wrankmore
Wirtschaftsprüfer
[certified public auditor]
Seite 9 von 9